These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
447 related articles for article (PubMed ID: 20232473)
1. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473 [TBL] [Abstract][Full Text] [Related]
2. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A; J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995 [TBL] [Abstract][Full Text] [Related]
3. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population. Bradbury R; Champion A; Reid DW Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887 [TBL] [Abstract][Full Text] [Related]
4. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. Hansen CR; Pressler T; Hoiby N; Johansen HK J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202 [TBL] [Abstract][Full Text] [Related]
5. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222 [TBL] [Abstract][Full Text] [Related]
6. Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa. Tingpej P; Elkins M; Rose B; Hu H; Moriarty C; Manos J; Barras B; Bye P; Harbour C Respirology; 2010 Aug; 15(6):923-9. PubMed ID: 20573059 [TBL] [Abstract][Full Text] [Related]
7. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350 [TBL] [Abstract][Full Text] [Related]
8. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms. Bosso JA; Mauldin PD; Steed LL Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687 [TBL] [Abstract][Full Text] [Related]
9. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. Perry JD; Laine L; Hughes S; Nicholson A; Galloway A; Gould FK J Antimicrob Chemother; 2008 May; 61(5):1057-61. PubMed ID: 18316821 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. Valenza G; Tappe D; Turnwald D; Frosch M; König C; Hebestreit H; Abele-Horn M J Cyst Fibros; 2008 Mar; 7(2):123-7. PubMed ID: 17693140 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary infection in mild variant cystic fibrosis: implications for care. Lording A; McGaw J; Dalton A; Beal G; Everard M; Taylor CJ J Cyst Fibros; 2006 May; 5(2):101-4. PubMed ID: 16426904 [TBL] [Abstract][Full Text] [Related]
12. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967 [TBL] [Abstract][Full Text] [Related]
13. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Hansen CR; Pressler T; Høiby N J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078 [TBL] [Abstract][Full Text] [Related]
14. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263 [TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781 [TBL] [Abstract][Full Text] [Related]
16. Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade. Raidt L; Idelevich EA; Dübbers A; Küster P; Drevinek P; Peters G; Kahl BC Pediatr Infect Dis J; 2015 Jul; 34(7):700-5. PubMed ID: 25851069 [TBL] [Abstract][Full Text] [Related]